Relay Therapeutics, Inc. (RLAY)
| Market Cap | 4.11B +334.7% |
| Revenue (ttm) | 10.35M +23.9% |
| Net Income | -286.04M |
| EPS | -1.57 |
| Shares Out | 219.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,879,813 |
| Open | 19.50 |
| Previous Close | 19.39 |
| Day's Range | 18.17 - 19.50 |
| 52-Week Range | 5.47 - 21.27 |
| Beta | 1.73 |
| Analysts | Strong Buy |
| Price Target | 27.58 (+47.17%) |
| Est. Earnings | Nov 5, 2026 |
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R... [Read more]
Financial Performance
In 2025, Relay Therapeutics's revenue was $15.36 million, an increase of 53.44% compared to the previous year's $10.01 million. Losses were -$276.48 million, -18.13% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $27.58, which is an increase of 47.17% from the latest price.
News
Relay Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Zovegalisib showed strong efficacy and tolerability in both breast cancer and vascular anomalies, with pivotal trials progressing and regulatory submissions planned. The addressable markets are substantial, and the company is well-funded to execute on multiple late-stage programs, with key data and regulatory milestones expected in the next year.
Relay Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Upcoming regulatory updates and data releases are expected for both breast cancer and vascular anomalies, with zovegalisib showing strong efficacy and safety profiles in both indications. The company is advancing toward pivotal trials and potential accelerated approvals, targeting significant market opportunities in chronic therapy.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...
Relay Therapeutics price target raised to $29 from $28 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Relay Therapeutics (RLAY) to $29 from $28 and keeps a Buy rating on the shares. The firm updated the company’s model post…
Relay Therapeutics price target raised to $31 from $28 at JPMorgan
JPMorgan analyst Priyanka Grover raised the firm’s price target on Relay Therapeutics (RLAY) to $31 from $28 and keeps an Overweight rating on the shares.
Relay Therapeutics price target raised to $25 from $21 at BofA
BofA raised the firm’s price target on Relay Therapeutics (RLAY) to $25 from $21 and keeps a Buy rating on the shares. The firm adjusted targets for several stocks in…
Relay Therapeutics price target raised to $26 from $21 at Citizens
Citizens raised the firm’s price target on Relay Therapeutics (RLAY) to $26 from $21 and keeps an Outperform rating on the shares. Relay Therapeutics is emerging as a potential backbone…
Relay Therapeutics price target raised to $30 from $27 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Relay Therapeutics (RLAY) to $30 from $27 and keeps an Overweight rating on the shares post the Q2 report. Relay’s…
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulator...
Relay Therapeutics Earnings release: Q2 2026
Relay Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Relay Therapeutics Quarterly report: Q2 2026
Relay Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics price target raised to $31 from $22 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Relay Therapeutics (RLAY) to $31 from $22 and keeps a Buy rating on the shares.
Relay Therapeutics initiated with a Buy at Canaccord on zovegalisib’s potential
As previously reported, Canaccord initiated coverage of Relay Therapeutics (RLAY) with a Buy rating and $29 price target The precision medicines company’s lead asset, zovegalisib, utilizes a precision...
Relay Therapeutics initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated coverage of Relay Therapeutics (RLAY) with a Buy rating and $29 price target
Relay Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Relay Therapeutics (RLAY) with an Overweight rating and $28 price target The firm views zovegalisib as “a credible multi-indication growth driver” for Relay, especially ...
Relay Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Zovega’s clinical programs in breast cancer and vascular anomalies are advancing, with strong efficacy and safety data supporting ongoing and planned phase III trials. Oral dosing and selective mechanisms provide competitive advantages, while regulatory and commercial strategies target accelerated approvals and broad market access.
Relay Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Three pivotal data sets were presented, including an oral regimen with 11-month PFS in breast cancer and paradigm-shifting results in vascular anomalies. Rapid trial progress, strong financials, and regulatory engagement support near-term advancement in both oncology and rare disease markets.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies f...
Relay Therapeutics price target raised to $26 from $22 at Guggenheim
Guggenheim raised the firm’s price target on Relay Therapeutics (RLAY) to $26 from $22 and keeps a Buy rating on the shares. The firm updated its model for recent financing…
Relay Therapeutics price target raised to $28 from $25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Relay Therapeutics (RLAY) to $28 from $25 and keeps a Buy rating on the shares after the company presented initial results from…
Relay Therapeutics 22.9M share Secondary priced at $12.00
The deal size was increased to $275M from $175M and priced below last closing price of $13.02. Jefferies, TD Cowen, Goldman Sachs, Guggenheim and Raymond James are acting as joint…
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies f...
Relay Therapeutics price target raised to $21 from $19 at Citizens
Citizens raised the firm’s price target on Relay Therapeutics (RLAY) to $21 from $19 and keeps an Outperform rating on the shares. Relay Therapeutics reported top-line data showing that zovegalisib…
Relay Therapeutics price target raised to $27 from $21 at Barclays
Barclays raised the firm’s price target on Relay Therapeutics (RLAY) to $27 from $21 and keeps an Overweight rating on the shares. The company’s zovegalisib clinical update positioned the drug…